Skip to main content
. 2023 Jan 5;29(2):197–205. doi: 10.3350/cmh.2022.0404

Figure 3.

Figure 3.

Treatment algorithm of systemic therapies for hepatocellular carcinoma. AFP, alpha-fetoprotein. *If patients have absolute or relative contraindications for immune-checkpoint inhibitors or bevacizumab, multiple tyrosine kinase inhibitors such as sorafenib or lenvatinib should be recommended. Adopted from 2022 KLCA-NCC HCC guidelines.